Agasti 2021: I-FDA inikeze i-loncastuximab tesirine-lpyl (i-Zynlonta, i-ADC Therapeutics SA), i-CD19 eqondiswe ku-antibody kanye ne-alkylating agent conjugate, evumela ukusheshiswa kweziguli ezindala ezine-B-cell enkulu ebuyile noma ephikisayo ..